



PRESS RELEASE

Noventure and RFSU enter into agreement to commercialize Utipro[®] Plus across Nordic countries

Barcelona, March 13, 2017 - Noventure and Riksförbundet för sexuell upplysning (RFSU), the Swedish Association for Sexuality Education, announce today that they have entered into an agreement by which RFSU will distribute Noventure's Utipro[®] Plus in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With this agreement, Utipro Plus is now available in 21 European countries.

Utipro Plus is a Class III CE marked medical device used to control and prevent uncomplicated urinary tract infections (UTIs) by relieving associated symptoms in the acute phase of the pathology as well as preventing relapses. Utipro Plus is available in capsules for oral use.

UTIs are infections of the lower urinary system resulting from the increased proliferation and ascent of intestinal bacteria. These contaminate the distal urethra and reach the bladder causing irritating symptoms such as dysuria, frequency, urgency, pain and bladder tenderness. Relapses are caused by the presence of bacterial reservoirs¹.

UTIs are among the most prevalent infectious diseases affecting women worldwide: approximately 13% of women between the age of 18 and 90 will have an annual incidence of UTIs².

Luciano Conde, CEO of Noventure said: "Utipro Plus offers an innovative approach to UTIs. After a successful introduction in other European countries, it can now help improve the wellbeing of women across the Nordic countries. This agreement with RFSU, a recognized leader in promoting women's health in the region, is an exciting opportunity for Noventure."

Katarina Knutz, CEO of RFSU AB said: "We are delighted to partner with Noventure and to be able to offer Utipro Plus, a unique product, to Nordic consumers. The benefit of preventing and relieving the symptoms of UTIs, reducing the usage of antibiotics, will be highly appreciated both by the physicians and patients. We see Utipro Plus as a product that will greatly improve women's health."

RFSU anticipates launching Utipro Plus in 2018.



Noventure's business model is based on offering exclusive commercial rights in selected regions to its distribution partners. Noventure's Utipro Plus is already available across Europe and worldwide through a number of partners.

Notes to Editors:

About RFSU

Riksförbundet för sexuell upplysning (The Swedish Association for Sexuality Education) is an NGO founded in 1933. Changing and improving people's lives have been RFSU's main objectives since the start.

RFSU AB is a company owned by the association offering high quality products within the categories of sex and relationships and also body care and wellbeing. The products are intended to give men and women a more pleasure-filled, safer sex life, increased wellbeing and a better quality of life.

The profits provide the RFSU with the resources needed to spread information and provide instruction about sex and relationships, domestically and internationally. When you buy a product, join as a member, cooperate or support RFSU's work, you are helping to continue to change people's lives.

www.rfsu.com

About Noventure

Noventure is a start-up enterprise, headquartered in Barcelona, specializing in licensing medical devices to partner companies. Noventure's products are natural polymers based on a proprietary barrier technology that reinforces the epithelia, thereby restoring its functionality. Noventure's areas of interest are gastrointestinal, paediatrics, urogynaecology, allergy and dermatology.

Noventure aims to build exclusive, long-term partnerships rooted in a shared understanding of the medical need and the marketing opportunity in each country, nurtured by close communication and teamwork. Currently Noventure has a network of partners and distributors that commercialize its products in more than 40 countries.

www.noventure.com

Media Contacts:

Andrew Lloyd & Associates
Agnes Stephens / Juliette dos Santos
agnes@ala.com / Juliette@ala.com
UK: + 44 1273 675 100
US: + 1 617 202 4491
@ALA_Group

References



1. *Guidelines on Urological infections – European Association of Urology, 2015*
2. *Ariel R. Brumbaugh – Expert Rev. Vaccines, June 2012*

Utipro[®] Plus is a Class III medical device. It fulfils all requirements in regard to current European legislation. For further information, refer to Utipro[®] Plus instructions. CE 0373.